Troriluzole

Troriluzole represents an innovative therapeutic approach for treating obsessive-compulsive disorder (OCD) by modulating glutamatergic neurotransmission. Hyperactive glutamate signaling has been increasingly implicated in the pathophysiology of OCD, making this agent a promising option for patients resistant to conventional serotonergic or dopaminergic therapies. A randomized, double-blind, placebo-controlled trial involving 244 adults demonstrated numerical improvements in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores, particularly among individuals with more severe baseline symptoms, although not all differences reached statistical significance. Currently, two ongoing multicenter Phase 3 trials (NCT04641143, NCT04693351) are further evaluating its efficacy and safety, with preliminary findings suggesting a favorable tolerability profile and potential clinical benefits. If confirmed in future studies, troriluzole could introduce the first novel pharmacological mechanism for OCD treatment in more than two decades, offering hope for patients unresponsive to existing interventions.